NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis $90.77 -1.68 (-1.82%) Closing price 04:00 PM EasternExtended Trading$86.05 -4.72 (-5.20%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rhythm Pharmaceuticals alerts:Sign Up Key Stats Today's Range$90.07▼$94.4750-Day Range$92.45▼$117.6052-Week Range$74.50▼$122.20Volume952,801 shsAverage Volume758,303 shsMarket Capitalization$6.22 billionP/E RatioN/ADividend YieldN/APrice Target$140.67Consensus RatingModerate Buy Company Overview Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for rare genetic diseases of obesity and other disorders involving the melanocortin-4 receptor (MC4R) pathway. The company’s research is centered on conditions in which genetic defects disrupt the body’s regulation of appetite, hunger and energy expenditure. Rhythm’s lead product is IMCIVREE (setmelanotide), an MC4R agonist designed to restore signaling in the brain’s melanocortin pathway. The therapy is approved in the United States for chronic weight management in adults and children with obesity caused by certain genetic deficiencies, including POMC, PCSK1 and LEPR deficiencies, as well as Bardet-Biedl syndrome. Setmelanotide is also authorized in the European Union for certain patients with genetically confirmed rare forms of obesity. Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm serves patients through commercial and medical operations in the United States and international markets. The company continues to study setmelanotide in additional rare genetic obesity populations and develop other potential treatments targeting the MC4R pathway. David Meeker has served as Rhythm’s president and chief executive officer.AI Generated. May Contain Errors. Read More Rhythm Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreRYTM MarketRank™: Rhythm Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 436th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on no strong buy ratings, 17 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialRhythm Pharmaceuticals has a consensus price target of $140.67, representing about 55.0% upside from its current price of $90.77.Amount of Analyst CoverageRhythm Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rhythm Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($2.86) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -29.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -29.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 43.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rhythm Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.95% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 20.06, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently decreased by 0.15%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.51 News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Rhythm Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,796,497.00 in company stock.Percentage Held by Insiders5.90% of the stock of Rhythm Pharmaceuticals is held by insiders.Percentage Held by InstitutionsRhythm Pharmaceuticals has minimal institutional ownership at this time.Read more about Rhythm Pharmaceuticals' insider trading history. Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RYTM Stock News HeadlinesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $140.67 According to BrokeragesSeptember 30, 2026 | americanbankingnews.comKuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmSeptember 28, 2026 | prnewswire.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.October 6 at 1:00 AM | Stansberry Research (Ad)Critical Comparison: Anika Therapeutics (NASDAQ:ANIK) and Rhythm Pharmaceuticals (NASDAQ:RYTM)September 28, 2026 | americanbankingnews.comRhythm Pops on Health Canada NodSeptember 23, 2026 | baystreet.caRhythm Pharmaceuticals, Inc. Announces Health Canada Approval Of IMCIVREE (Setmelanotide) For Weight Management In Adult And Pediatric Patients 4 Years Of Age And Older With ...September 23, 2026 | marketscreener.comMRhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with ...September 22, 2026 | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells $5,133,500.00 in StockSeptember 15, 2026 | insidertrades.comSee More Headlines RYTM Stock Analysis - Frequently Asked Questions How have RYTM shares performed this year? Rhythm Pharmaceuticals' stock was trading at $107.04 at the beginning of 2026. Since then, RYTM stock has decreased by 15.2% and is now trading at $90.77. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.08. The firm's revenue was up 46.9% on a year-over-year basis. Read the conference call transcript. When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $106 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 7,050,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/04/2026Today10/06/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 RYTM's financial health is in the Green zone, according to TradeSmith. RYTM has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RYTM CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees414Year Founded2008Price Target and Rating Average Price Target for Rhythm Pharmaceuticals$140.67 High Price Target$160.00 Low Price Target$100.00 Potential Upside/Downside+54.7%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$196.54 million Net Margins-85.59% Pretax Margin-85.14% Return on Equity-159.87% Return on Assets-44.00% Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.20 Sales & Book Value Annual Sales$239.92 million Price / Sales25.98 Cash FlowN/A Price / Cash FlowN/A Book Value$2.08 per share Price / Book43.73Miscellaneous Outstanding Shares68,533,000Free Float64,490,000Market Cap$6.23 billion OptionableOptionable Beta2.01 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:RYTM) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
